Glutaminase Agonists

Cat.No. Product Name Information Product Use Citations Product Validations
S8620 6-Diazo-5-oxo-L-norleucine (Diazooxonorleucine) 6-Diazo-5-oxo-L-norleucine (Diazooxonorleucine, L-6-Diazo-5-oxonorleucine, DON), an antibiotic isolated from Streptomyces, is a glutaminase antagonist with IC50 of ~1 mM for cKGA (kidney-type glutaminase). 6-Diazo-5-oxo-L-norleucine exhibits analgesic, antibacterial, antiviral and anticancer properties.
bioRxiv, 2025, 2025.07.14.664742
Int J Mol Sci, 2024, 25(18)10183
iScience, 2023, 26(10):107790
S8891 JHU-083 JHU-083 (Ethyl 2-(2-Amino-4-methylpentanamido)-DON) is a novel prodrug of DON. This compound selectively blocks glutaminase activity in brain CD11b+ cells and prevents depression-associated behaviours induced by chronic social defeat stress.Solutions are unstable and should be fresh-prepared.
Cell Rep, 2025, 44(5):115596
iScience, 2023, 26(10):107790
S8892 JHU395 JHU395 is a novel orally bioavailable GA (glutamine antagonists) prodrug designed to circulate inert in plasma, but permeate and release active GA within target tissues. This compound delivers active GA to malignant peripheral nerve sheath tumour (MPNST), and significantly inhibits tumour growth without observed toxicity.
E1203 Sirpiglenastat (DRP-104) Sirpiglenastat (DRP-104) is a broad acting glutamine antagonist. It has anticancer effects by directly targeting tumour metabolism and simultaneously inducing a potent anti-tumour immune response with immunomodulatory and antineoplastic activities.